Home > Healthcare > Pharmaceuticals > Finished Drug Form > Infectious Enteritis Treatment Market

Infectious Enteritis Treatment Market Trends

Report ID: GMI9216
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Infectious Enteritis Treatment Market Trends

Factors such as the increasing population affected by irritable bowel syndrome (IBS) and diarrhea due to infectious enteritis, coupled with extensive research and development endeavours contribute to market expansion.

For instance, a study published in the Middle East Journal of Digestive Diseases estimated an IBS incidence of 38.5 per 10,000 persons annually, with a prevalence of 10-17% in the general population. Similarly, research published in BMC Medicine indicates that 10-20% of IBS cases develop following acute gastroenteritis. This heightened prevalence surged the escalating demand for treatment options, thereby driving the market growth.
Furthermore, initiatives by key market players such as product launches, mergers, acquisitions, and partnerships, are anticipated to bolster market expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The infectious enteritis treatment market size was valued at USD 434.8 million in 2023 and will grow at 6.3% CAGR from 2024 to 2032, propelled by the rising incidence of infectious diseases globally.

Infectious enteritis treatment industry from the antibiotics drug type segment will reach USD 388.5 million by end of 2032, owing to its ability to effectively target various enteric infections in adults.

U.S. infectious enteritis treatment market size was 167.9 million in 2023 and will show significant growth over the analysis period, driven by favorable regulatory frameworks, coupled with the introduction of advanced products.

Abbott Laboratories, Almirall SA, AstraZeneca PLC, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, GSK plc, Medimetriks Pharmaceuticals Inc., Merck KGaA, and Pfizer Inc. among others.